Manufacturing Facilities
Delivering high quality products across the globe

11 manufacturing facilities across 4 countries

Monroe, US

Spread across 100,000 sq.ft., this facility will manufacture oral solids, injectable and nebulized products.
Estimated investment is approximately USD 100 Mn over 5 years.

Regulatory Approvals

  • Pending for approval

Markets

USA

Annual Capacity

Oral solids: 300 - 400 Mn tablets and capsules

Injectables: 20 - 25 Mn vials and pre-filled syringes

Inhalation: 25 - 30 mn ampules

Goa, India

The facility commenced operations in 2004.
Three manufacturing facilities for production of:
  • Oral – solids
  • Semi-solids
  • Hormones (oral solids)

ISO 14001: 2004 approved

Regulatory Approvals

  • US-FDA
  • TPD (Canada)
  • MCC (South Africa)
  • WHO – GMP
  • ANVISA (Brazil)
  • MHRA (UK)

Markets

North America, Western Europe

Annual Capacity

Oral solid dosages (OSD): 4000 Mn tablets and 608 Mn capsules

Semi-solids: 21 Mn tubes

Hormone: 400 Mn tablets

Baddi, India

This state-of-the-art manufacturing facility commenced operations in 2005.
The facility caters to the production of oral solids and liquid orals, external preparations like lotions, creams and respiratory segment products.

ISO 14001: 2004 approved

Regulatory Approvals

  • US-FDA
  • WHO-GMP
  • ANVISA Brazil
  • MHRA UK
  • MCC South Africa
  • TGA Australia
  • NDA Uganda
  • Ukrainian GMP
  • DDA Nepal
  • TPD Canada
  • FDA Ghana
  • CHMP Kenya

Markets

USA, Europe, India , Other semi-regulated markets for specific dosage forms

Annual Capacity

Oral solids: 800 Mn tablets / capsules

Liquids: 60 Mn bottles

External preparations: 20 Mn tubes

Respiratory segment: 15 Mn units

Nalagarh, India

The facility commenced operations in 2009.
The plant has three main sections for manufacturing liquid, ointments or creams and lotions.

ISO 14001: 2004 approved

Regulatory Approvals

  • ANVISA Brazil
  • NDA – Uganda
  • WHO-GMP
  • Local FDA

Markets

India, Asia, Africa

Annual Capacity

Oral liquids: 45 million bottles

Ointments and creams: 45 million units

Lotions: 22 million bottles

Sikkim, India

Established in 2012, the facility is focused on manufacturing oral solid dosages.

ISO 14001: 2004 approved

Regulatory Approvals

  • Local FDA

Markets

India

Annual Capacity

Oral Solid dosages : 835 million tablets

Nashik, India

Glenmark’s first manufacturing unit, it began operations in 1983.
The facility manufactures products catering to demand in oral solids, liquid orals, external creams and powder shampoo.

ISO 14001: 2004 approved

Regulatory Approvals

  • WHO – GMP
  • ANVISA (Brazil)
  • NDA – Uganda
  • MOH – Nigeria
  • TFDA – Tanzania
  • MOH – Ethiopia
  • MOH – Congo
  • MCC – South Africa
  • MOH – Oman
  • MOH – Ukraine
  • INVIMA – Columbia

Markets

Asia, India, Africa, CIS / Russia, Latin America

Annual Capacity

Oral solids: 270 Mn tablets / capsules

Oral Liquids: 27 Mn bottles

External preparations: 50 Mn units

Powder Shampoo: 20 Mn units

Indore, India

The Indore facility initiated operations in May 2009.

ISO 14001: 2004 approved

Click to view the Biomedical waste generation data 2020-21

Regulatory Approvals

  • US-FDA
  • UK MHRA
  • WHO – GMP

Markets

North America, Europe

Annual Capacity

Oral solid dosages: 1440 Mn tablets.

Buenos Aires, Argentina

The Glenmark manufacturing site at Buenos Aires, Argentina is focused on manufacturing of Oncology Injectables.
The plant is spread across 30,000 sq. ft. and it serves as a global hub for manufacturing Lyophilized and Liquid Injectables used in oncology therapies.

ISO 14001: 2004 approved

Regulatory Approvals

  • US-FDA
  • ANMAT Argentina
  • MERCOSUR

Markets

Brazil, Latin America, India

Annual Capacity

Injectables: 3.5 Mn vials

Vysoke Myto, Czech Republic

This manufacturing facility, formerly known as Medicamenta, was set-up in 1952 and was acquired by Glenmark in 2009. Presently the facility manufactures solid-orals and semi-solids (ointments).

OHSAS certification

Regulatory Approvals

  • Manufacturing licence for medicinal products (Issued by SUKL)
  • Distribution licence for medicinal products (Issued by SUKL)
  • Certificate of GMP Compliance of Manufacturer (Issued by SUKL)
  • Certificate of GMP Compliance of a Manufacturer (Issued by USKVBL)

Markets

Czech and Slovak Republics, Poland, Romania, Hungry, Other European Union territories

Annual Capacity

Oral solid dosages: 144 Mn tablets

Ointments and creams: 1.5 Mn tubes

Aurangabad, India

Glenmark’s Aurangabad facility initiated operations in April 2012.
Aurangabad site is focused in the manufacturing Formulations (OSD, Inhaler, Foam & API). This plant is spread over 30 acres and it serves to both domestic and international markets.

ISO 14001: 2015 approved, OHSAS 18001: 2007 approved

Regulatory Approvals

  • US-FDA
  • UK MHRA
  • WHO – GMP
  • ANMAT
  • ANVISA

Markets

Domestic, US, Brazil

Annual Capacity

API : Crofelemer : 1.2 MT

API : Telmisartan : 11 MT

API : Oxcarbazepine : 20 MT

Formulation : Tablet : 12 Mn

Formulation : MDI : 3.5 Mn

Formulation : DPI Device : 2 Mn

Formulation : Topical Foam : 0.6 Mn

Quality at Glenmark

Setting new benchmarks through delivery of high quality products across all geographies
Know More